



Drug Discovery 2014
 Manchester Central Convention Centre
 2nd+3rd Sept '14
 www.elrig.org
 #ELRIGDD14

Session Summary

Day 2 : Wed 3rd Sept'14
Room : Charter 3
09:10 - 17:00

Engineered Proteins for Therapy

Biological therapeutics are set to lead the novel drugs market for the foreseeable future. The current dominance of essentially unmodified monoclonal antibody drugs will give way to novel biologics that promise improved efficacy with enhanced safety and disposition profiles. This session will contrast existing macromolecular therapeutic approaches with emerging, novel engineered protein therapies.

CHAIRS : Phil Blandward, Sweet Spot Therapeutics, John McCafferty, Cambridge University			
TIME	SPEAKER	TITLE	
9:10	Session Chairs	Introduction and Welcome	
9:15	Lutz Jermutus, MedImmune	Novel targets and antibody add-ons	Session Keynote
10:00	Bill Eldridge, Cyclogenix	The cyclotide microprotein family as a scaffold for drug discovery and delivery	
10:30	COFFEE BREAK		
11:00	Davis Farmer, MSM Protein Technologies	An Established and Reliable Technology for the Generation of High-Affinity Functional Monoclonal Antibodies to Complex Membrane Proteins	
11:30	Poster Taster Session		
12:00	Snapshots		
12:30	LUNCH, Exhibition, Posters, Lunchtime Workshops		
2:00	Sebastian Mayer, GSK	AlbudAb™: A serum half-life extension platform	
2:30	David Gilham, University of Manchester	Engineering Chimeric Antigen Receptors for Cancer Immunotherapy	
3:00	<i>To be confirmed</i>		
3:30	COFFEE BREAK		
4:00	Panel Discussion		In Charter 1
5:00	Close of Conference / Prizes		
5:15	CLOSE		

Publication date 09/06/14. More detail, abstracts, speaker biogs, etc, are available on our website : www.elrig.org



It's FREE to attend Drug Discovery '14 as a delegate.
 Register here or go to www.elrig.org